Is Peptide Receptor Radionuclide Therapy Effective in the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer?—A Case Report
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) represents a major clinical challenge due to its limited response to conventional treatment and poor prognosis. Peptide receptor radionuclide therapy (PRRT) has emerged as a promising treatment modality in patients with somatostatin receptor (SSTR)-positive tumors. We present an 82-year-old female patient with RAIR-DTC who underwent six cycles of PRRT after demonstrating SSTR positivity on Ga-68 DOTATATE positron emission tomography/computed tomography. This case highlights the limited therapeutic efficacy of PRRT in RAIR-DTC, despite favorable imaging characteristics. It underscores the need for better patient selection and further research to clarify the role of PRRT in this population.
Fields of Study & Subjects
Thyroid Cancer Diagnosis and Treatment
Radiopharmaceutical Chemistry and Applications
Neuroendocrine Tumor Research Advances
Publication details
- Journal / source
- Nigerian Journal of Clinical Practice
- Volume
- 29
- Issue
- 3
- Pages
- 360–363
- Publication date
- 1 March 2026
- Language
- EN